BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $17.20 Million Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 14.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 759,887 shares of the company’s stock after selling 128,194 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 1.60% of Bicycle Therapeutics worth $17,196,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in BCYC. Price T Rowe Associates Inc. MD grew its position in Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock worth $10,001,000 after purchasing an additional 124,809 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in Bicycle Therapeutics by 27.2% during the second quarter. Harbor Capital Advisors Inc. now owns 55,289 shares of the company’s stock worth $1,119,000 after buying an additional 11,809 shares in the last quarter. Pinnacle Associates Ltd. grew its position in Bicycle Therapeutics by 202.2% during the second quarter. Pinnacle Associates Ltd. now owns 242,001 shares of the company’s stock worth $4,898,000 after buying an additional 161,911 shares in the last quarter. Natixis Advisors LLC acquired a new position in Bicycle Therapeutics in the 2nd quarter valued at approximately $261,000. Finally, TD Asset Management Inc raised its holdings in Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after acquiring an additional 42,200 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. Stephens initiated coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Finally, B. Riley lowered shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $33.00 to $28.00 in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.13.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,212 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the transaction, the chief executive officer now owns 380,864 shares of the company’s stock, valued at $8,478,032.64. This represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the sale, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,840 shares of company stock worth $259,128 over the last 90 days. Insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Trading Up 1.4 %

Shares of NASDAQ BCYC opened at $20.54 on Friday. Bicycle Therapeutics plc has a 1-year low of $13.31 and a 1-year high of $28.67. The company has a 50-day moving average of $23.97 and a two-hundred day moving average of $23.04. The company has a market cap of $976.68 million, a PE ratio of -6.24 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. The firm had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue for the quarter was down 50.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.26) EPS. As a group, equities research analysts forecast that Bicycle Therapeutics plc will post -3.07 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.